Burning Rock Biotech Ltd

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue and liquid biopsy tests for therapy selection and prognosis prediction across many cancer types, including lung, gastrointestinal, prostate, breast, lymphoma, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. Key products include OncoScreen Focus, OncoScreen Plus, OncoCompass Plus, OncoCompass Target, ColonCore, CanCatch, OncoMaster, and Magnis BR. It also facilitates laboratory equipment sales and sells reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China, and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Founded in 2014, Burning Rock Biotech Limited is headquartered in Guangzhou, China.